Science

Pashtoon Kasi Shares Results from LODESTAR Trial on Rucaparib in HRR-Mutated Solid Tumors

Pashtoon Kasi/LinkedIn

Jun 2, 2025, 16:15

Pashtoon Kasi Shares Results from LODESTAR Trial on Rucaparib in HRR-Mutated Solid Tumors

Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope Orange County, shared a post on X:

“This is what excites me. Precision Oncology agnostic of tissue type. We enrolled patients with a variety of cancers to this 1st AGNOSTIC PARP trial. Long journey.

Finally over the finishing line.

BRCA, PALB2, RAD, BARD, and more.”

Title: LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes.

Authors: Sriram Anbil, Nicholas Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Kasi, Douglas Laux, Gary Schwartz, Geoffrey Shapiro, Kevin Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa Schrock, Shuoguo Wang, Ethan Sokol, Brennan Decker, Katherine Nathanson, Susan Domchek, Kim Reiss

Read the Full Abstract

Pashtoon Kasi

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Science

OncoDaily

Science

Pashtoon Kasi Shares Results from LODESTAR Trial on Rucaparib in HRR-Mutated Solid Tumors

“This is what excites me. Precision Oncology agnostic of tissue type. We enrolled patients with a variety of cancers to this 1st AGNOSTIC PARP trial. Long journey.

Finally over the finishing line.

BRCA, PALB2, RAD, BARD, and more.”